The deal adds hepatitis B and early-stage shingles vaccines as Sanofi faces pipeline pressure from tolebrutinib setback.

Dec 24 (Reuters) - Sanofi (SASY.PA) said on Wednesday it will buy U.S. biotech Dynavax Technologies (DVAX.O) for around $2.2 ...

Shares of Dynavax Technologies (NASDAQ: DVAX) popped on Wednesday after the vaccine maker struck a deal to be acquired by Sanofi (NASDAQ: SNY). As of 3:00 p.m. EST, Dynavax's stock price was up more ...

The French drugmaker is looking to dealmaking after some experimental drugs missed their goals in clinical studies or were ...

The Dow Jones Industrial Average climbed 0.6% to 48,731.16, while the S&P 500 added 0.32% to close at 6,932.05.

Dynavax's adult hepatitis B vaccine HEPLISAV-B is currently marketed in the US and is differentiated by its two-dose regimen over one month, which enables high levels of seroprotection faster than ...

The deal gives Sanofi access to Dynavax’s approved hepatitis B vaccine, News.Az reports, citing Reuters. This acquisition ...

Sanofi has announced an agreement to acquire U.S.-based vaccines company Dynavax Technologies in an all-cash transaction ...

Here are some of the stocks making notable moves in Wednesday's premarket action: Dynavax Technologies stock is up 37% after ...

Sanofi acquires Dynavax for $2.2B, boosting its vaccine portfolio with HEPLISAV-B and a shingles candidate. Click for my ...

Sanofi (SNY) to acquire Dynavax Technologies (DVAX) for $15.50 per share in cash, expanding its presence in adult ...

Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline Paris, December 24, 2025.